ImClone Investigational Site

St Louis, Missouri 63136

0 studies enrolling now · 10 studies all time

What they study most

Adipocytic Sarcoma, Breast Cancer, Colorectal Cancer, Colorectal Neoplasms, Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Hepatocellular Carcinoma, Leiomyosarcoma, Metastases, Neoplasm, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Cancer, Prostate Cancer

Studies at this site

• Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer — Completed
• A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma — Completed
• A Study of Olaratumab in Soft Tissue Sarcoma — Completed
• A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer — Completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy — Completed
• Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed